Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
CING Cingulate
0.951-0.049-4.90%
Close
01/27 16:00 ET
0.9510.0000.00%
Post Mkt Price 01/27 19:28 ET
High
1.030
Open
1.010
Turnover
11.53K
Low
0.951
Pre Close
1.000
Volume
11.49K
Post-Market
5D
1D
1W
1M
1Q
1Y
Price Forecast
News
Comment
Short Interest in Cingulate Inc. (NASDAQ:CING) Decreases By 22.4%
Cingulate Inc. (NASDAQ:CING – Get Rating) was the recipient of a large decline in short interest in the month of December. As of December 30th, there was short interest totalling 82,100 shares, a de
Cingulate's (CING) Buy Rating Reaffirmed at HC Wainwright
HC Wainwright reiterated their buy rating on shares of Cingulate (NASDAQ:CING – Get Rating) in a research note issued to investors on Tuesday, The Fly reports. HC Wainwright also issued estimates fo
Cingulate Initiated at Buy by HC Wainwright & Co.
Cingulate Price Target Announced at $5.50/Share by HC Wainwright & Co.
Cingulate Price Target Announced at $5.50/Share by HC Wainwright & Co.
Cingulate Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 01/17/2023 459.63% HC Wainwright & Co. → $5.5 Initiates Coverage On → Buy 11/22/2022 205.25% Maxim Group →
HC Wainwright & Co. Initiates Coverage On Cingulate With Buy Rating, Announces Price Target of $5.5
HC Wainwright & Co. analyst Raghuram Selvaraju initiates coverage on Cingulate (NASDAQ:CING) with a Buy rating and announces Price Target of $5.5.
Cingulate Initiated With a Buy at H.C. Wainwright
Cingulate (NASDAQ:CING) Shares Down 10.8%
Shares of Cingulate Inc. (NASDAQ:CING – Get Rating) were down 10.8% during mid-day trading on Monday . The stock traded as low as $0.90 and last traded at $0.95. Approximately 151,205 shares changed
GE, ENVX and KALA Among Pre Market Losers
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
GainersGeron (NASDAQ:GERN) shares increased by 57.1% to $3.77 during Wednesday's pre-market session. The company's market cap stands at $1.4 billion. Tenax Therapeutics (NASDAQ:TENX) stock increased b
Company Overview
More
Cingulate, Inc. operates as a clinical stage bio pharmaceutical company using Precision Timed Release, drug delivery platform technology to build a pipeline of next-generation pharmaceutical products. The firm initially focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD). It identifies and evaluates additional therapeutic areas, PTR technology employed to develop future product candidates. Cingulate was founded by Shane J. Schaffer, Craig Steven Gilgallon, Raul R. Silva, Matthew N. Brams in 2013 and is headquartered in Kansas City, KS.
CEO： Dr. Shane J. Schaffer, Pharm.D.
Market： NASDAQ
Listing Date： 12/08/2021
Paper Trade
More
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
Watchlist
No Stock Yet